ERBB2 and breast carcinoma: In contrast, the current standard treatment strategies for patients with stage N2-3 breast cancer are local surgery plus chemotherapy and postoperative adjuvant radiotherapy (RT), endocrine therapy for hormone receptor (HoR)-positive patients, and targeted therapy for human epidermal growth factor receptor-2 (HER2)-positive tumors (7, 8).